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ABSTRACT 
The poor aqueous solubility of the drug exhibits in variable dissolution rate and hence poor bioavailability. Aceclofenac is poorly 
water soluble drug. The aim of the present study was to improve the water solubility and the dissolution rate of Aceclofenac by 
solid dispersion technique using different water soluble polymers. The term solid dispersions refer to the dispersions of one or 
more active ingredients in an inert carrier or matrix at solid state. In this study, binary solid dispersion of Aceclofenac were 
prepared by fusion method using Polyethylene glycol 6000 (PEG 6000), Polyethylene glycol 4000 (PEG 4000), Poloxamer as 
carrier. Different drug-carrier weight ratio was used for this study. The effect of the carrier on the solubility and in-vitro 
dissolution were studied. It was found the drug was released 26.86% after 5 minutes and only 40.19% within 60 mins from active 
Aceclofenac on the other hand the release pattern of Aceclofenac from the binary solid dispersion formulations containing PEG 
6000 in 1:5 ratio (Formulation coding: A5) showed the best result in comparison of other binary and ternary solid dispersion 
formulations which was 62.29% after 5 min and 83.03% within 60 mins. The hydrophilic polymers used for the preparation of 
solid dispersion are showed significant increase in the solubility of Aceclofenac.  
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INTRODUCTION 
Poorly water-soluble drugs are increasingly becoming 
a problem in terms of obtaining the satisfactory 
dissolution within the gastrointestinal tract that is 
necessary for good bioavailability
1
. It is not only 
existing drugs that cause problems but it is the 
challenge of medicinal chemists to ensure that new 
drugs are not only active pharmacologically but have 
enough solubility to ensure fast enough dissolution at 
the site of administration, often gastrointestinal tract. 
Therefore efforts to increase drug dissolution are often 
needed
2
. Aceclofenac is a new generation NSAID used 
in the treatment of osteoarthritis, rheumatoid arthritis 
and other joint diseases
3
. It is chemically designated as 
2-[(2,6-diclorophenyl) amine] phenyl acetoxy acetic 
acid). Solid dispersions of aceclofenac were formulated 
to overcome problems like gastric irritation and other 
side effects that are frequently experienced with 
NSAID drug therapy
4
. Aceclofenac is practically 
insoluble in water leading to poor dissolution
5
. 
Aceclofenac appears to be well tolerated among 
NSAIDs with a lower incident of gastro intestinal 
adverse effects
6
. The biopharmaceutical classification 
system (BCS) divides all drug candidates into four 
different groups according to their solubility and 
permeability. Aceclofenac is an example of BCS class 
II compound (highly permeable and low Soluble), its 
oral bioavailability is determined by dissolution rate in 
the gastro intestinal tract. Therefore the improvement 
of Aceclofenac dissolution is an important issue for 
enhancing its bioavailability and therapeutic efficacy
7
. 
Solubility is the property of a solid, liquid, or gaseous 
chemical substance called solute to dissolve in a solid, 
liquid, or gaseous solvent to form a homogeneous 
solution of the solute in the solvent. Most often, the 
solvent is a liquid, which can be a pure substance or a 
mixture
7
. One may also speak of solid solution but 
rarely of solution in a gas
8
.
 
The term solid dispersion 
refers to a group of solid products consisting of at least 
two different components, generally a hydrophilic 
matrix and a hydrophobic drug. The matrix can be 
either crystalline or amorphous. The drug can be 
dispersed molecularly, in amorphous particles 
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(clusters) or in crystalline particles
9
. For drugs with 
high crystal energy, higher amorphous compositions 
can be obtained by choosing carriers, which exhibit 
specific interactions with them
10
. 
Present study has been designed with purpose to 
improve the water solubility of Aceclofenac which is 
insoluble in water at active ingredient. The dissolution 
rate of Aceclofenac is expected to limit its absoption 
from the GIT. In this study, fusion method and 
solubility test has been used to develop solid dispersion 
of drug. There are various polymers which have been 
used in this technique to form porous and amorphous 
micro particle of solid dispersion helps in the reduction 
of dose of the drug. Aceclofenac has been chosen as a 
water insoluble model drug PEG 6000, PEG 4000 and 
Poloxamer have been used as the hydrophilic polymers 
which were employed as a carrier material for 
formulation of solid dispersion with model drug. 
 
MATERIALS AND METHODS 
Aceclofenac and Polyethylene Glycol 4000 were 
obtained from Albion Laboratories Ltd, Chittagong, 
Bangladesh. Poloxamer, Potassium di-hydrogen 
phosphate, Di-Potassium hydrogen phosphate were 
obtained from Merck, Germany. 
Preparaion of Solid dispersion formulations 
Aceclofenac solid dispersions formulations were 
prepared by Fusion method
11
. Desired amount of drug 
and polymer (PEG 4000, PEG 6000 and Poloxamer) 
weighted out accurately (Table 1). 
Then PEG was taken in a beaker. Put it in to hot water 
bath for melting at 70°C. After melting PEG 
(liquid)/Polymer, desired amount of Aceclofenac was 
added to that glass beaker. Then it was mixed properly 
to obtain viscous mass. The mixture was stirred 
robustly for uniformed mixing by using glass rod. After 
melting, it was kept in normal room temperature for 
five days until getting solid mass. The solidified 
mixture was then withdrawn from glass beaker and 
grinded by mortar and pestle. Obtained solid 
preparation powder was passed through the sieve 
(mesh size 40). Finally it was kept in glass vial with 
proper labeling and stored in a dessicator until further 
use. 
In vitro dissolution study of solid dispersion 
formulations 
The in-vitro dissolution tests were performed for the 
pure Aceclofenac and solid dispersions; using USP 
dissolution test apparatus type II using 900 ml of 
phosphate buffer as dissolution medium with the assay. 
We used this media to compare the dissolution profile 
of pure drug with that of prepared binary and ternary 
solid dispersions. The temperature of the medium was 
maintained at 37°C±0.5°C throughout the experiment. 
The samples containing 50 mg of Aceclofenac or its 
equivalent solid dispersions were placed in the 
dissolution medium. Paddle was used at a stirring rate 
of 50 rpm. A 5ml solution was withdrawn at 
predetermined time intervals of at 5, 15, 30, 45 and 60 
minutes and then 5 ml of fresh dissolution medium was 
replaced to maintain the constant volume of dissolution 
medium. The absorbance of solution was measured at 
275 nm by using UV spectrophotometer against 
dissolution medium as phosphate buffer. Percentage of 
drug release was calculated
12
.  
 
RESULTS AND DISCUSSION 
Aceclofenac is a poor water soluble oral dosage form 
with problems of variable bioavailability and 
bioequivalence related to its poor water solubility. The 
present study was aimed to observe release pattern of 
drug from solid dispersions by using different 
excipients such as PEG6000, PEG4000 etc. From the 
obtained data (Figure 1) it was shown that release 
pattern from solid dispersions formulations A5 shows 
the best result in comparison to A1, A2 and A3 which 
was 83.03% within an hour. The release pattern from 
solid dispersions formulations A14 shows the best 
result in comparison to A15 which was 54.13% within 
an hour (Figure 2). 
The release pattern from solid dispersions formulations 
A6 shows the best result in comparison to A7, A8 and 
A9 which was 81.38 % within an hour (Figure 3). 
The results indicates that that release pattern from solid 
dispersions formulations A10 shows the best result in 
comparison to A11, A12 and A13 which was 74.55% 
within an hour (Figure 4). The solid dispersions of 
aceclofenac prepared by PEG 6000 and PEG 4000 at 
1:3 ratio was compared with each other. When 
comparing the solid dispersions of aceclofenac 
containing two polymers, A3 (with PEG6000) gave the 
best result (Figure 5). 
The solid dispersions of aceclofenac prepared with 
PEG6000 and PEG 4000 at 1:5 ratios was compared 
with each other. When comparing the solid dispersions 
of aceclofenac containing same polymer, A5 (with 
PEG6000) gave the best result (Figure 6). The solid 
dispersions of aceclofenac prepared with PEG6000and 
PEG 4000 and Poloxamer at 1:1:0.75 ratios was 
compared with each other. When comparing the solid 
dispersions of aceclofenac containing same polymer, 
A6 (with PEG6000 and Poloxamer) gave the best result 
(Figure 7). The solid dispersions of aceclofenac 
prepared with PEG6000and PEG 4000 and Poloxamer 
at 1:1:0.25 ratios was compared with each other. When 
comparing the solid dispersions of aceclofenac 
containing same polymer, A8 (with PEG6000 and 
Poloxamer) gave the best result. 
From the above result, we can conclude that the 
dissolution rate of the solid dispersions increases in 
compared with active drug when aceclofenac was 
dispersed in different water soluble carrier. As the 
soluble carriers dissolve, the insoluble drug is exposed 
to dissolution medium as very fine particles leading to 
increase in both surface area and solubilization for fast 
dissolution and absorption (Figure 8).  
15 solid dispersions formulations (aceclofenac with 
different polymer) dissolution data were analyzed by 
zero order model, first order, Higuchi square root 
equation and Hixon Crowell cube root law (Figure 9 to 
Figure 16)
13
. 
The above data showed that R
2
 value of active 
Aceclofenac, (R
2
=0.979) and all solid dispersions 
formulations except A1 were found substantially 
highest result in case of Higuchi release kinetics than 
other release kinetics. These R
2
 value is near about 01, 
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so it can be said that, active Aceclofenac, all solid 
dispersions formulations except A1 were followed zero 
order release pattern. 
A1(R
2
=0.828) was displayed best fitting with 
Hixoncrowell release kinetics pattern. Because R
2
 
value of A1 was showed better value in case of 
Hixoncrowell release kinetics (Table 2). 
It was also observed that, in all case no formulation 
was fitted with First order release kinetics model. 
 
CONCLUSION 
Aceclofenac is a poorly water soluble drug. The 
enhancement of oral bioavailability of poor water 
soluble drugs remains one of the most challenging 
aspects of drug perfection. Various scientists achieved 
a complete dissolution of drug from solid dispersions 
by using different hydrophilic carriers. The carriers 
acted as dispersing for the liberated drug, thus 
preventing the formation of any water- insoluble 
surface layers. In the present study, solid dispersions of 
Aceclofenac with different hydrophilic carriers in 
different ratios were prepared by Fusion method to 
improve water solubility and dissolution 
characteristics. The preparation of solid dispersions by 
solvent evaporation technique has been proven to be 
successful. This research showed that when 
Aceclofenac was dispersed in suitable water-soluble 
carriers such as PEG 6000, PEG 4000, Poloxamer, its 
dissolution were enhanced compared with pure drug. 
Among all water soluble carriers, the solid dispersions 
formulations containing PEG 6000at 1:5 ratios (binary 
formulation) gave the best result. Fusion method is 
effective to increase the release rate of Aceclofenac. 
The water soluble carrier may operate in the micro 
environment (diffusion layer) immediately surrounding 
the drug particles in the early stage of dissolution, since 
the carrier completely dissolves in short time thus 
enhancing the solubility and dissolution of drug. The 
drug –polymer interaction were investigated by Fourier 
Transform Infrared spectroscopy and no considerable 
drug-polymer interactions were found. However, the 
shape and surface morphology are important 
consideration for solid dispersions characterization. So, 
further studies Differential Scanning Calorimetry, 
Scanning Electronic Microscopy and X-ray diffractions 
have to be conducted in this aspect to know the nature 
of drug whether it is in crystalline form or amorphous. 
Finally in vivo study will require for final selection of 
carrier and to produce a successful drug delivery 
system. 
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Table 1: Composition of solid dispersion formulations of Aceclofenac. 
Code Carriers Drug 
polymer             
ratio 
Code Carriers Drug polymer             
ratio 
A1 PEG 6000 1:1 A9 PEG 6000:Poloxamer 1:1:00 
A2 PEG 6000 1:2 A10 PEG4000:Poloxamer 1:1:0.75 
A3 PEG 6000 1:3 A11 PEG4000:Poloxamer 1:1:0.50 
A4 PEG 6000 1:4 A12 PEG4000:Poloxamer 1:1:0.25 
A5 PEG 6000 1:5 A13 PEG4000:Poloxamer 1:1:00 
A6 PEG6000:Poloxamer 1:1:0.75 A14 PEG 4000 1:3 
A7 PEG 6000:Poloxamer 1:1:0.50 A15 PEG 4000 1:5 
A8 PEG 6000:Poloxamer 1:1:0.25    
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Figure 1:Percent release of aceclofenac from active drug and solid dispersion (SD) formulations containing 
different ratio of PEG 6000 with different ratio 
 
Figure 2: Percent release of Aceclofenac from active drug and solid dispersion (SD) formulations containing 
different ratio of  PEG 4000 
 
 
Figure 3: Percent release of Aceclofenac solid dispersion formulations containing different ratio of PEG 6000 
and Poloxamer 
 
 
Figure 4: Percent release of Aceclofenac from active drug and solid dispersion formulations containing 
different ratio of PEG 4000 and Poloxamer 
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Figure 5: Average % release of drug from solid dispersion formulations containing PEG 4000 and PEG 6000 
 
Figure 6: Comparison between PEG 6000 and PEG 4000 on release of Aceclofenac at 1:5 ratio. 
 
Figure 7: Comparison among PEG 6000, PEG 4000 and Poloxamer on release of Aceclofenac at 1:1:0.75 ratio 
(Ternary formulation). 
 
Figure 8: Comparison among PEG 6000, PEG 4000 and Poloxamer on release of Aceclofenac at 1:1:0.25 ratio. 
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Figure 9: Zero order Plots of solid dispersion formulations (PEG 6000 and Poloxamer 
 
Table 2: Y equation and R
2
 values of solid dispersion formulations and active Aceclofenac (API) 
Code Zero order First order Higuchi  model Hixon  model 
 Y equation R2 
value 
Y equation R2 
value 
Y equation R2 
value 
Y equation R2 
value 
API 0.513x+15.47 0.621 -0.003x+1.922 0.675 6.679x+10.52 0.842 -0.009x+4.378 0.657 
A1 0.671x+28.65 0.470 0.007x+1.830 0.556 18.6x+45.50 0.707 -.014x+4.098 0.828 
A2 0.675x+25.97 0.525 0.004x+1.853 0.609 12.16x+26.74 0.769 -0.014x+4.112 0.313 
A3 0.607x+28.14 0.431 -0.004x+1.835 0.505 8.469x+23.53 0.672 -0.012x+4.112 0.478 
A4 0.883x+40.63 0.436 -0.009x+1.706 0.606 0.954x+26.2 0.692 -0.023x+3.768 0.543 
A5 0.948x+8.79 0.490 0.010x+1.790 0.683 8.781x+20.14 0.748 -0.23x+3.826 0.613 
A6 0.886x+36.22 0.494 -0.007x+1.768 0.692 17.51x+42.2 0.752 -0.023x+3.196 0.620 
A7 0.838x+37.42 0.451 -0.007x+1.749 0.611 18.65x+48.99 0.700 -0.021x+3.872 0.551 
A9 0.732x+34.37 0.426 -0.005x+1.779 0.529 20.63x+57.03 0.677 -0.016x+3.954 0.490 
A10 0.838x+31.35 0.539 -0.007x+1.814 0.710 16.26x+35.45 0.768 -0.020x+4.045 0.650 
A11 0.657x+34.21 0.377 -0.004x+1.779 0.440 15.15x+46.88 0.626 -0.014x+3.957 0.416 
A12 0.672x+29.67 0.454 -0.004x+1.821 0.538 16x+48.02 0.641 -0.014x+4.073 0.508 
A13 0.557x+28.31 0.388 -0.003x+1.833 0.436 16x+48.02 0.641 1.135x+11.95 0.684 
A14 0.554x+27.94 0.392 -0.003x+1.836 0.441 7.917x+ 0.640 -0.011x+4.115 0.423 
A15 0.473x+18.91 0.504 -0..2x+1.901 0.560 6.472x+14.74 0.755 -0.008x+4.311 0.540 
 
 
 
 
 
 
            Figure 10: Zero order plots of solid dispersion formulations (PEG 4000 and Poloxamer) 
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Figure 11: Comparative study of first order release kinetics of solid dispersion formulations (PEG 4000 and 
Poloxamer) 
 
 
 
 
 
Figure 12: First order release kinetics of solid dispersion formulations (PEG 4000 and Poloxamer). 
 
 
 
 
 
 
Figure 13: Higuchi release kinetics of solid dispersion formulations (PEG 6000 and poloxamer). 
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Figure 14: Higuchi release kinetics of solid dispersion formulations (PEG 4000 and poloxamer). 
 
 
 
 
Figure 15: Comparative study of Hixon Crowell release of solid dispersion formulations (PEG 6000 and 
Poloxamer) 
 
 
 
Figure 16: Comparative study of Hixon Crowell release of solid dispersion formulations (PEG 4000 and 
Poloxamer) 
 
 
